First world's patient enrolled in the PANACEA study for women with HER2 positive breast cancer

Intro text: 

An Australian woman has recently become the first world's patient enrolled in the international clinical trial PANACEA. The study, conducted under the BIG umbrella, will test the anti-tumour activity of a new drug called KEYTRUDA when combined with trastuzumab, in women with HER2 positive breast cancer.


What is 'PANACEA'?

'PANACEA' stands for: anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer. This international clinical trial was designed for women diagnosed with advanced HER2 positive breast cancer.

What is the objective?

The PANACEA trial aims to determine the most suitable dose of KEYTRUDA (pembrolizumab, MK-3475) and trastuzumab when these drugs are used together and to assess if their combined use is an effective anti-cancer treatment.

Find out all details here.

Coordinating research groups:

The global study is being led by the International Breast Cancer Study Group (IBCSG) under the (Breast International Group) BIG umbrella. In Australia, where the First Patient was included, the trial is coordinated by the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG).

ANZBCTG is proud to announce the recruitment of the first world's patient in the study! Read the full Press Release dated 28 April 2015.